DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-065/S-001

Bristol-Myers Squibb Company
Attention: Meenal Pai, Pharm.D.
5 Research Pkwy, Signature 91, 3Sig-3021
Wallingford, CT 06492

Dear Dr. Pai:

Please refer to your supplemental new drug application dated February 19, 2008, received February 19, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ixempra™ (ixabepilone).

This supplemental new drug application provides for labeling and chemistry, manufacturing, and controls information for additional recommended infusion fluids for dilution, in addition to Lactated Ringers Injection, USP.

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling (text for the package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA22-065/S-001."

The final printed labeling (FPL) for the carton and container labels must be identical to the immediate container and carton labels submitted February 19, 2008.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alberta Davis-Warren, Regulatory Health Project Manager, at (301) 796-

Sincerely,

{See appended electronic signature page}

Robert Justice, M.D.
Director
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert Justice

3/13/2009 06:52:44 PM